Drug Comparisons by Disease and Genetics
The effect of a disease is not the same in every person who has it. Genetics shape which pathway is broken, how quickly the condition progresses, and which therapeutic class has a realistic chance of working. These comparisons summarize how we evaluate treatment approaches within each disease area, and what genetic context each approach depends on.
This page is research reference material for scientific and partner audiences. It describes therapeutic classes and mechanisms in general terms and is not medical advice or a treatment recommendation.
Oncology
Tumors of the same tissue can carry entirely different driver mutations, so treatment selection depends far more on molecular profile than on organ of origin.
Targeted kinase inhibitors
Mechanism: Block a specific signaling protein that a tumor depends on for growth.
Genetic dependency: Requires an activating driver alteration in the target gene. Resistance mutations often reduce benefit over time.
Immune checkpoint modulation
Mechanism: Release the brakes on the immune system so it can recognize tumor cells.
Genetic dependency: Associated with high mutational burden and mismatch repair deficiency, which increase the number of recognizable tumor antigens.
DNA repair directed agents
Mechanism: Exploit a tumor's inability to repair DNA damage, causing lethal genomic instability.
Genetic dependency: Depends on defects in homologous recombination repair genes, a classic synthetic lethal relationship.
Parkinson's disease
Most cases are sporadic, but monogenic forms behave differently in progression and in response to mechanism specific therapies.
Dopaminergic replacement
Mechanism: Restores dopamine signaling to reduce motor symptoms without altering underlying pathology.
Genetic dependency: Broadly symptomatic. Onset age and dyskinesia risk vary with genetic background.
Lysosomal and glucocerebrosidase directed strategies
Mechanism: Aim to restore protein clearance pathways that fail in disease.
Genetic dependency: Most relevant to carriers of variants affecting lysosomal function, where the mechanism is directly implicated.
Kinase pathway modulation
Mechanism: Targets overactive signaling linked to neuronal stress and degeneration.
Genetic dependency: Rationale is strongest in patients with activating variants in the relevant kinase gene.
Dementia and Alzheimer's disease
Risk genotype influences both the biology of protein accumulation and the safety profile of some treatment classes.
Amyloid directed biologics
Mechanism: Promote clearance of accumulated amyloid protein from the brain.
Genetic dependency: Carrier status for known risk alleles is closely tied to imaging related safety findings and to expected benefit.
Tau directed strategies
Mechanism: Aim to limit the spread of misfolded tau along neural networks.
Genetic dependency: Particularly relevant where tau pathology is primary, including inherited tauopathies.
Symptomatic neurotransmitter support
Mechanism: Improves cognitive symptoms without changing the disease course.
Genetic dependency: Largely genotype independent, which is why it complements rather than replaces mechanism directed therapy.
Epilepsy
Ion channel genotype can make the same medicine helpful in one patient and harmful in another, one of the clearest examples of genetics driven treatment selection.
Sodium channel blockers
Mechanism: Reduce repetitive neuronal firing by dampening sodium currents.
Genetic dependency: Effective in gain of function channel variants, but can worsen seizures in certain loss of function developmental epilepsies.
Synaptic vesicle protein modulators
Mechanism: Alter neurotransmitter release to reduce network excitability.
Genetic dependency: Broad spectrum activity with comparatively limited genotype dependence.
Precision genetic therapies
Mechanism: Correct or compensate for a specific causal variant rather than suppress symptoms.
Genetic dependency: Applicable only to patients with a confirmed causal variant identified by genetic testing.
Rare monogenic disease
A single causal variant defines the condition, so the comparison is usually between correcting, replacing, or bypassing the affected gene product.
Small molecule correctors and modulators
Mechanism: Help a partially functional protein fold or work more effectively.
Genetic dependency: Variant class specific. Benefit differs sharply between missense and null variants.
Nucleic acid therapies
Mechanism: Modify transcript processing or expression to restore functional protein.
Genetic dependency: Often designed around one variant or a small set of related variants.
Drug repurposing
Mechanism: Applies an existing approved medicine to a newly understood mechanism.
Genetic dependency: Depends on whether the affected pathway overlaps with a pathway already served by an existing therapy.
How these comparisons are built
Each comparison combines published evidence with our own analysis, and is refined with the modeling described on our artificial intelligence in drug comparison page. Genetic context comes from genomics and personalized medicine, and patient identification depends on diagnostics and biomarkers.